Anneke J. van der Kooi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anneke J. van der Kooi has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Joost Raaphorst
Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
8 shared publications - Marianne de Visser
Department of Neurology, Amsterdam Neuroscience Amsterdam University Medical Centre, Location Academic Medical Centre, University of Amsterdam Amsterdam the Netherlands
5 shared publications - Eleonora Aronica
Department of (Neuro)pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
4 shared publications - Andrea Schwarz Doria
Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, ON, Canada
3 shared publications - Daniel Brito de Araujo
Universidade Federal de Pelotas, Brasil
3 shared publications - Edoardo Conticini
Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy
3 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (6) , 315
Associations of cognitive and behavioural impairment in ALS with brain pathology: pTDP-43 versus microglial activation
Objective: Investigate associations between brain pathology (pTDP-43 inclusions and microglial activation) and cognitive and behavioural impairment in patients with amyotrophic lateral sclerosis (ALS). Methods: Based on comprehensive neuropsychological examination and behavioural assessment, 21 ALS patients of whom post mortem brain tissue was obtained, were classified as having 1) no cognitive and/or behavioural impairment (pure motor ALS), 2) mild cognitive and/or behavioural impairment (ALSci/bi), and 3) ALS with behavioural variant frontotemporal dementia (ALS-bvFTD). Immunohistochemical staining of pTDP-43 and HLA-DR-defined microglial activation was semi-quantitatively assessed in grey and/or white matter of the prefrontal cortex, thalamus, hippocampus, and motor cortex. Results: Fourteen patients had pure motor ALS, four patients had ALSci/bi, and three patients had ALS-bvFTD. pTDP-43 pathology in the grey matter of the prefrontal cortex and gyrus dentatus differed between groups, especially between pure motor ALS and ALS-bvFTD. For each extra-motor brain region, pTDP-43 severity was highest in patients with ALS-bvFTD and lowest in patients with pure motor ALS, with ALSci/bi in between. This pattern was not observed for microglial activation. Associations between white matter pTDP-43 severity and cognitive/behavioural impairment were less robust than those in grey matter. Conclusion: Severity of cognitive and/or behavioural impairment in ALS is related to severity of pTDP-43 pathology, in particular in the grey matter of extra-motor brain regions; we did not detect a clear association with microglial activation.
- 15 May 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (6) , 315
Open AccessAssociations of cognitive and behavioural impairment in ALS with brain pathology: pTDP-43 versus microglial activation
Objective: Investigate associations between brain pathology (pTDP-43 inclusions and microglial activation) and cognitive and behavioural impairment in patients with amyotrophic lateral sclerosis (ALS). Methods: Based on comprehensive neuropsychological examination and behavioural assessment, 21 ALS patients of whom post mortem brain tissue was obtained, were classified as having 1) no cognitive and/or behavioural impairment (pure motor ALS), 2) mild cognitive and/or behavioural impairment (ALSci/bi), and 3) ALS with behavioural variant frontotemporal dementia (ALS-bvFTD). Immunohistochemical staining of pTDP-43 and HLA-DR-defined microglial activation was semi-quantitatively assessed in grey and/or white matter of the prefrontal cortex, thalamus, hippocampus, and motor cortex. Results: Fourteen patients had pure motor ALS, four patients had ALSci/bi, and three patients had ALS-bvFTD. pTDP-43 pathology in the grey matter of the prefrontal cortex and gyrus dentatus differed between groups, especially between pure motor ALS and ALS-bvFTD. For each extra-motor brain region, pTDP-43 severity was highest in patients with ALS-bvFTD and lowest in patients with pure motor ALS, with ALSci/bi in between. This pattern was not observed for microglial activation. Associations between white matter pTDP-43 severity and cognitive/behavioural impairment were less robust than those in grey matter. Conclusion: Severity of cognitive and/or behavioural impairment in ALS is related to severity of pTDP-43 pathology, in particular in the grey matter of extra-motor brain regions; we did not detect a clear association with microglial activation.
- Open Access
- 7 November 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 75, 152865
Magnetic resonance imaging for adult idiopathic inflammatory myopathies: A scoping review of protocols, grading systems and applications
- 7 November 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 75, 152865
Open AccessMagnetic resonance imaging for adult idiopathic inflammatory myopathies: A scoping review of protocols, grading systems and applications
- Open Access
Rhabdomyolysis in the Era of Next-Generation Sequencing: Selecting Patients with a High Likelihood of a Genetic Susceptibility Using ‘RHABDO’ Features
Background/Objectives: Rhabdomyolysis is a potentially life-threatening condition characterized by acute skeletal muscle breakdown. In addition to well-described external triggers, a genetic contribution is increasingly recognized. We aimed to (I) review the genetic diagnostic approach of rhabdomyolysis, (II) evaluate the clinical characteristics indicative of a genetic susceptibility with the ‘RHABDO’ acronym, and (III) assess the predictive value of the presence RHABDO features for identifying genetic variants. Methods: In this retrospective two-center study, 122 patients underwent genetic testing for rhabdomyolysis since the introduction of whole exome sequencing (WES) in 2013. The presence of RHABDO features was compared between those with (likely) pathogenic variants and those with benign or no identified variants or variants of uncertain significance. Results: The testing methods included panel-based WES (82%), Sanger sequencing (49%), and full WES (24%), of which 52 patients (43%) underwent multiple methods. A (likely) pathogenic variant was identified in 13 patients (11%), in all of whom ≥2 RHABDO features were present. The positive predictive value for ≥2 features was 14%, while the negative predictive value was 100%. Conclusions: These results highlight the relevance of WES in further elucidating the genetic basis of rhabdomyolysis and demonstrated that RHABDO is a valuable tool for selecting patients who should undergo genetic testing.
Open AccessRhabdomyolysis in the Era of Next-Generation Sequencing: Selecting Patients with a High Likelihood of a Genetic Susceptibility Using ‘RHABDO’ Features
Background/Objectives: Rhabdomyolysis is a potentially life-threatening condition characterized by acute skeletal muscle breakdown. In addition to well-described external triggers, a genetic contribution is increasingly recognized. We aimed to (I) review the genetic diagnostic approach of rhabdomyolysis, (II) evaluate the clinical characteristics indicative of a genetic susceptibility with the ‘RHABDO’ acronym, and (III) assess the predictive value of the presence RHABDO features for identifying genetic variants. Methods: In this retrospective two-center study, 122 patients underwent genetic testing for rhabdomyolysis since the introduction of whole exome sequencing (WES) in 2013. The presence of RHABDO features was compared between those with (likely) pathogenic variants and those with benign or no identified variants or variants of uncertain significance. Results: The testing methods included panel-based WES (82%), Sanger sequencing (49%), and full WES (24%), of which 52 patients (43%) underwent multiple methods. A (likely) pathogenic variant was identified in 13 patients (11%), in all of whom ≥2 RHABDO features were present. The positive predictive value for ≥2 features was 14%, while the negative predictive value was 100%. Conclusions: These results highlight the relevance of WES in further elucidating the genetic basis of rhabdomyolysis and demonstrated that RHABDO is a valuable tool for selecting patients who should undergo genetic testing.
- Open Access
- 17 July 2025
- Published by MIT Press in Network Neuroscience
- Vol. 9 (3) , 824-841
Longitudinal changes in MEG-based brain network topology of ALS patients with cognitive/behavioral impairment—An exploratory study
Amyotrophic lateral sclerosis (ALS) with only motor impairment (ALS-pure motor) and the behavioral variant of frontotemporal dementia (bvFTD) are hypothesized to represent extreme ends of a disease spectrum, which encompasses ALS with cognitive/behavioral impairment (ALSci/bi). In this longitudinal magnetoencephalography (MEG) study, we investigated changes in brain network topology of ALSci/bi over time as compared with ALS-pure motor and bvFTD patients. Resting-state MEG was recorded in ALS-pure motor (n = 9), ALSci/bi (n = 16), and bvFTD (n = 16) at baseline and 5-month follow-up, projected to source space. The corrected version of the amplitude envelope correlation was applied to compute frequency-band-specific functional connectivity between brain regions, from which the backbone of the functional networks was constructed using the minimum spanning tree (MST) approach. Reference MSTs were computed based on the functional connectivity matrices for ALS-pure motor and bvFTD, against which the networks of ALSci/bi were compared. We showed that, at baseline, networks in the theta band of ALSci/bi patients were more similar to ALS-pure motor than bvFTD. At follow-up, ALSci/bi patients’ beta-band network similarity had moved away from ALS-pure motor and resembled bvFTD. In conclusion, our findings suggest that brain networks of ALSci/bi patients move along the ALS-bvFTD spectrum over time, from ALS-pure motor to bvFTD-like topology.
- 17 July 2025
- Published by MIT Press in Network Neuroscience
- Vol. 9 (3) , 824-841
Open AccessLongitudinal changes in MEG-based brain network topology of ALS patients with cognitive/behavioral impairment—An exploratory study
Amyotrophic lateral sclerosis (ALS) with only motor impairment (ALS-pure motor) and the behavioral variant of frontotemporal dementia (bvFTD) are hypothesized to represent extreme ends of a disease spectrum, which encompasses ALS with cognitive/behavioral impairment (ALSci/bi). In this longitudinal magnetoencephalography (MEG) study, we investigated changes in brain network topology of ALSci/bi over time as compared with ALS-pure motor and bvFTD patients. Resting-state MEG was recorded in ALS-pure motor (n = 9), ALSci/bi (n = 16), and bvFTD (n = 16) at baseline and 5-month follow-up, projected to source space. The corrected version of the amplitude envelope correlation was applied to compute frequency-band-specific functional connectivity between brain regions, from which the backbone of the functional networks was constructed using the minimum spanning tree (MST) approach. Reference MSTs were computed based on the functional connectivity matrices for ALS-pure motor and bvFTD, against which the networks of ALSci/bi were compared. We showed that, at baseline, networks in the theta band of ALSci/bi patients were more similar to ALS-pure motor than bvFTD. At follow-up, ALSci/bi patients’ beta-band network similarity had moved away from ALS-pure motor and resembled bvFTD. In conclusion, our findings suggest that brain networks of ALSci/bi patients move along the ALS-bvFTD spectrum over time, from ALS-pure motor to bvFTD-like topology.
- Open Access
- 14 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 465
Methodology Development for Investigating Pathophysiological [18F]-FDG Muscle Uptake in Patients with Rheumatic Musculoskeletal Diseases
Objectives: This retrospective study explored the qualitative and quantitative assessment of F18-fluordeoxyglucose ([18F]-FDG) positron emission tomography and computed tomography (PET/CT) scans to assess pathophysiological muscle glucose uptake in patients with a rheumatic musculoskeletal disease (RMD). [18F]-FDG PET/CT detects metabolic activity via glucose uptake in tissues. This study aimed to determine the feasibility of quantitative assessment of [18F]-FDG uptake in muscles across three different RMDs compared to controls. Methods: In this study we analysed whole-body [18F]-FDG PET/CT scans from patients with rheumatoid arthritis (RA; n = 11), osteoarthritis (OA; n = 10), and idiopathic inflammatory myositis (IIM; n = 10), and non-RMD controls (n = 11), focusing on muscle-tracer uptake in specific muscle groups. Qualitative assessment visually identified regions with high [18F]-FDG uptake, followed by quantitative assessment using two methods: fixed volume-of-interest (VOI) and hotspot VOI. In the fixed VOI method, a VOI was placed in the respective muscle at a fixed position (50% height from proximal to distal end) on PET/CT images. In the hotspot VOI method, the VOI was placed at the site of the highest [18F]-FDG uptake observed during qualitative assessment. Standardised uptake values (SUVs) were determined for different muscle groups between RMDs and controls. Results: Qualitative assessment revealed a heterogenous uptake pattern of [18F]-FDG that was found in 93% of quadriceps and hamstring muscles, while other muscles displayed either heterogenous or homogenous patterns. A Bland–Altman analysis showed that the hotspot VOI method had a higher sensitivity in detecting differential [18F]-FDG uptake in muscles. Across all muscle groups, patients with IIM had the highest [18F]-FDG uptake, followed by patients with OA and RA, respectively. Conclusions: [18F]-FDG PET/CT enables qualitative and quantitative differentiation of muscle glucose uptake in patients with RA, OA, and IIM, at both individual muscle and patient group levels. The hotspot method and SUVpeak are recommended for quantitative assessment. High [18F]-FDG uptake in multiple muscle groups suggests pathophysiological glucose metabolism in RMD-affected muscles.
- 14 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 465
Open AccessMethodology Development for Investigating Pathophysiological [18F]-FDG Muscle Uptake in Patients with Rheumatic Musculoskeletal Diseases
Objectives: This retrospective study explored the qualitative and quantitative assessment of F18-fluordeoxyglucose ([18F]-FDG) positron emission tomography and computed tomography (PET/CT) scans to assess pathophysiological muscle glucose uptake in patients with a rheumatic musculoskeletal disease (RMD). [18F]-FDG PET/CT detects metabolic activity via glucose uptake in tissues. This study aimed to determine the feasibility of quantitative assessment of [18F]-FDG uptake in muscles across three different RMDs compared to controls. Methods: In this study we analysed whole-body [18F]-FDG PET/CT scans from patients with rheumatoid arthritis (RA; n = 11), osteoarthritis (OA; n = 10), and idiopathic inflammatory myositis (IIM; n = 10), and non-RMD controls (n = 11), focusing on muscle-tracer uptake in specific muscle groups. Qualitative assessment visually identified regions with high [18F]-FDG uptake, followed by quantitative assessment using two methods: fixed volume-of-interest (VOI) and hotspot VOI. In the fixed VOI method, a VOI was placed in the respective muscle at a fixed position (50% height from proximal to distal end) on PET/CT images. In the hotspot VOI method, the VOI was placed at the site of the highest [18F]-FDG uptake observed during qualitative assessment. Standardised uptake values (SUVs) were determined for different muscle groups between RMDs and controls. Results: Qualitative assessment revealed a heterogenous uptake pattern of [18F]-FDG that was found in 93% of quadriceps and hamstring muscles, while other muscles displayed either heterogenous or homogenous patterns. A Bland–Altman analysis showed that the hotspot VOI method had a higher sensitivity in detecting differential [18F]-FDG uptake in muscles. Across all muscle groups, patients with IIM had the highest [18F]-FDG uptake, followed by patients with OA and RA, respectively. Conclusions: [18F]-FDG PET/CT enables qualitative and quantitative differentiation of muscle glucose uptake in patients with RA, OA, and IIM, at both individual muscle and patient group levels. The hotspot method and SUVpeak are recommended for quantitative assessment. High [18F]-FDG uptake in multiple muscle groups suggests pathophysiological glucose metabolism in RMD-affected muscles.
- 8 July 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2403-2409
A protocol for scoping reviews on the role of whole-body and dedicated body-part magnetic resonance imaging for assessment of adult and juvenile idiopathic inflammatory myopathies
Currently, standardized magnetic resonance imaging (MRI) scoring systems and protocols for assessment of idiopathic inflammatory myopathies (IIMs) in children and adults are lacking. Therefore, we will perform a scoping review of the literature to collate and evaluate the existing semi-quantitative and quantitative MRI scoring systems and protocols for the assessment and monitoring of skeletal muscle involvement in patients with IIMs. The aim is to compile evidence-based information that will facilitate the future development of a universal standardized MRI scoring system for both research and clinical applications in IIM. A systematic search of electronic databases (PubMed, EMBASE, and Cochrane) will be undertaken to identify relevant articles published between January 2000 and October 2023. Data will be synthesized narratively. This scoping review seeks to comprehensively summarize and evaluate the evidence on the scanning protocols and scoring systems used in the assessment of diagnosis, disease activity, and damage using skeletal muscle MRI in IIMs. The results will allow the development of consensus recommendations for clinical practice and enable the standardization of research methods for the MRI assessment of skeletal muscle changes in patients with IIMs.
- 8 July 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2403-2409
A protocol for scoping reviews on the role of whole-body and dedicated body-part magnetic resonance imaging for assessment of adult and juvenile idiopathic inflammatory myopathies
Currently, standardized magnetic resonance imaging (MRI) scoring systems and protocols for assessment of idiopathic inflammatory myopathies (IIMs) in children and adults are lacking. Therefore, we will perform a scoping review of the literature to collate and evaluate the existing semi-quantitative and quantitative MRI scoring systems and protocols for the assessment and monitoring of skeletal muscle involvement in patients with IIMs. The aim is to compile evidence-based information that will facilitate the future development of a universal standardized MRI scoring system for both research and clinical applications in IIM. A systematic search of electronic databases (PubMed, EMBASE, and Cochrane) will be undertaken to identify relevant articles published between January 2000 and October 2023. Data will be synthesized narratively. This scoping review seeks to comprehensively summarize and evaluate the evidence on the scanning protocols and scoring systems used in the assessment of diagnosis, disease activity, and damage using skeletal muscle MRI in IIMs. The results will allow the development of consensus recommendations for clinical practice and enable the standardization of research methods for the MRI assessment of skeletal muscle changes in patients with IIMs.
- Open Access
A protocol for a scoping review on the role of whole-body and dedicated body-part magnetic resonance imaging for assessment of adult and juvenile idiopathic inflammatory myopathies
Background Currently, there is lack of standardization of magnetic resonance imaging (MRI) scoring systems and protocols for assessment of idiopathic inflammatory myopathies (IIMs) in children and adults among treatment centres across the globe. Therefore, we will perform scoping reviews of the literature to inform available semi-quantitative and quantitative MRI scoring systems and protocols for the assessment and monitoring of skeletal muscle involvement in patients with IIMs with the final goal of providing evidence-based information for the future development of a universal standardized MRI scoring system in specific research and clinical settings in this population. Methods Electronic databases (PubMed, EMBASE, and Cochrane) will be searched to select relevant articles published from January 2000 to October 2023. Data will be synthesized narratively. Discussion This scoping review will extensively map evidence on the indications, utility for diagnosis and assessment of disease activity and damage using skeletal muscle MRI in IIMs. The results will allow the development of consensus recommendations for clinical practice and enable the standardization of research methods for MRI assessment of skeletal muscle changes in patients with IIMs.
Open AccessA protocol for a scoping review on the role of whole-body and dedicated body-part magnetic resonance imaging for assessment of adult and juvenile idiopathic inflammatory myopathies
Background Currently, there is lack of standardization of magnetic resonance imaging (MRI) scoring systems and protocols for assessment of idiopathic inflammatory myopathies (IIMs) in children and adults among treatment centres across the globe. Therefore, we will perform scoping reviews of the literature to inform available semi-quantitative and quantitative MRI scoring systems and protocols for the assessment and monitoring of skeletal muscle involvement in patients with IIMs with the final goal of providing evidence-based information for the future development of a universal standardized MRI scoring system in specific research and clinical settings in this population. Methods Electronic databases (PubMed, EMBASE, and Cochrane) will be searched to select relevant articles published from January 2000 to October 2023. Data will be synthesized narratively. Discussion This scoping review will extensively map evidence on the indications, utility for diagnosis and assessment of disease activity and damage using skeletal muscle MRI in IIMs. The results will allow the development of consensus recommendations for clinical practice and enable the standardization of research methods for MRI assessment of skeletal muscle changes in patients with IIMs.
- Open Access
- 2 December 2023
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 76, 272.e3-272.e5
Successful treatment of respiratory failure in Hirayama disease
- 2 December 2023
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 76, 272.e3-272.e5
Open AccessSuccessful treatment of respiratory failure in Hirayama disease
- Open Access
- 7 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 574
POS0603 AUTOANTIBODIES AGAINST A SUBUNIT OF MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX I IN INCLUSION BODY MYOSITIS
Background Autoantibodies are found in up to 80% of patients with idiopathic inflammatory myopathies (IIM) and are associated with distinct clinical phenotypes [1]. Autoantibodies targeting cytosolic 5´-nucleotidase 1A (anti-cN1A) are currently the only known serum biomarker for the subgroup inclusion body myositis (IBM) (2), although detected even in other autoimmune diseases. Objectives To identify new autoimmune targets in IIM by antigen bead array assay. Methods In a first cross-sectional exploratory study, 357 antigens representing 268 proteins were incubated with plasma samples from 219 IIM (108 Polymyositis (PM), 80 Dermatomyositis (DM) and 31 IBM) patients, 349 Systemic Lupus Erythematosus (SLE) patients and 306 population controls for screening of IgG reactivity by antigen bead array. All samples were identified in the local biobank of the Rheumatology clinic, Karolinska University Hospital. Interesting results obtained for the IBM subgroup were then validated in an independent larger cohort of 287 patients with IBM followed at nine European rheumatological or neurological centers. IBM serum samples were explored by antigen bead array and results validated by western blot. As controls, serum samples from 30 patients with PM and 30 with DM, HLA-matched with the IBM Swedish cohort, were included. Demographics, laboratory, clinical, and muscle biopsy data of the IBM cohort was retrieved. Results In the exploratory study IgG reactivity towards NADH dehydrogenase 1 α subcomplex 11 (NDUFA11), a subunit of the membrane-bound mitochondrial respiratory chain complex I, was discovered with higher frequency in the IBM (9,7%) than PM (2,8%) and DM samples (2,5%), although the difference was not statistically significant. Anti-NDUFA11 IgG was also found in 2,3% of SLE and 2,6% of population control samples. In the validation study anti-NDUFA11 autoantibodies were detected in 11/287 IBM patients (3,8%), 0/30 PM and 0/30 DM patients. Reactivity against NDUFA11 could be confirmed by western blot (Table 1, Figure 1). The eleven anti-NDUFA11 positive patients showed a trend of lower frequency of wheelchair/walker ever use and higher creatine kinase levels at time of IBM diagnosis compared to the anti-NDUFA11 negative group. Ragged red fibers were significantly more prevalent in anti-NDUFA11 positive than negative patients (p=0.04). Anti-cN1A autoantibodies were detected in 98/287 (34,1%) of IBM, 3/30 (10%) DM and 9/29 (31%) PM patients, p=0.03. Coexistence of anti NDUFA11 and anti-cN1A antibodies was observed in 3 IBM patients. Conclusion Our results reveal a new autoimmune target in the mitochondrial respiratory chain complex I that might be specifically associated with IBM. This is of particular interest as mitochondrial abnormalities are known histological findings in muscle biopsies of IBM patients. References [1]Galindo-Feria AS, Wang G, Lundberg IE. Autoantibodies: Pathogenic or epiphenomenon. Best Pract Res Clin Rheumatol. 2022;36(2):101767. [2]Herbert MK,et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016;75(4):696-701. NDUFA11 protein fragments (PrESTs) Legend Amino acid sequence and molecular weight of the protein fragments loaded on the western blot gel. NDUFA11, NADH dehydrogenase 1 α subcomplex 11; His6ABP, six histidine and albumin binding protein. Validation of bead array assay results with western blot Legend Western blot showing the reactivity of two IBM patients against the NDUFA11 protein fragments (PrEST1,2,3) expressed with a His6ABP tag. Patient#1 was reactive to PrEST1 and not to PrEST2 and 3 in the bead array assay while patient#2 did not display any reactivity. NDUFA11, NADH dehydrogenase 1 α subcomplex 11; His6ABP, six histidine and albumin binding protein. Disclosure of Interests Antonella Notarnicola: None declared, Cecilia Hellstrom: None declared, Begum Horuluoglu: None declared, Charlotta Preger: None declared, Francesco Bonomi: None declared, Boel De Paepe: None declared, Jan De Bleecker: None declared, Anneke J. van der Kooi: None declared, Marianne de Visser: None declared, Sabrina Sacconi: None declared, Pedro Machado: None declared, Umesh A. Badrising: None declared, Anke Rietveld: None declared, Ger Pruijn: None declared, Simon Rothwell: None declared, James B. Lilleker: None declared, Hector Chinoy: None declared, Olivier Benveniste: None declared, Elisabet Svenungsson: None declared, Helena Idborg: None declared, Per-Johan Jakobsson: None declared, Peter Nilsson: None declared, Ingrid E. Lundberg Shareholder of: stock shares in Roche and Novartis, Consultant of: Consulting fees from Corbus Pharmaceuticals, Inc and research grants from Astra Zeneca and has been serving on the advisory board for Astra Zeneca, Bristol Myers Squibb, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezaar, Orphazyme, Pfizer and Janssen.
- 7 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 574
Open AccessPOS0603 AUTOANTIBODIES AGAINST A SUBUNIT OF MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX I IN INCLUSION BODY MYOSITIS
Background Autoantibodies are found in up to 80% of patients with idiopathic inflammatory myopathies (IIM) and are associated with distinct clinical phenotypes [1]. Autoantibodies targeting cytosolic 5´-nucleotidase 1A (anti-cN1A) are currently the only known serum biomarker for the subgroup inclusion body myositis (IBM) (2), although detected even in other autoimmune diseases. Objectives To identify new autoimmune targets in IIM by antigen bead array assay. Methods In a first cross-sectional exploratory study, 357 antigens representing 268 proteins were incubated with plasma samples from 219 IIM (108 Polymyositis (PM), 80 Dermatomyositis (DM) and 31 IBM) patients, 349 Systemic Lupus Erythematosus (SLE) patients and 306 population controls for screening of IgG reactivity by antigen bead array. All samples were identified in the local biobank of the Rheumatology clinic, Karolinska University Hospital. Interesting results obtained for the IBM subgroup were then validated in an independent larger cohort of 287 patients with IBM followed at nine European rheumatological or neurological centers. IBM serum samples were explored by antigen bead array and results validated by western blot. As controls, serum samples from 30 patients with PM and 30 with DM, HLA-matched with the IBM Swedish cohort, were included. Demographics, laboratory, clinical, and muscle biopsy data of the IBM cohort was retrieved. Results In the exploratory study IgG reactivity towards NADH dehydrogenase 1 α subcomplex 11 (NDUFA11), a subunit of the membrane-bound mitochondrial respiratory chain complex I, was discovered with higher frequency in the IBM (9,7%) than PM (2,8%) and DM samples (2,5%), although the difference was not statistically significant. Anti-NDUFA11 IgG was also found in 2,3% of SLE and 2,6% of population control samples. In the validation study anti-NDUFA11 autoantibodies were detected in 11/287 IBM patients (3,8%), 0/30 PM and 0/30 DM patients. Reactivity against NDUFA11 could be confirmed by western blot (Table 1, Figure 1). The eleven anti-NDUFA11 positive patients showed a trend of lower frequency of wheelchair/walker ever use and higher creatine kinase levels at time of IBM diagnosis compared to the anti-NDUFA11 negative group. Ragged red fibers were significantly more prevalent in anti-NDUFA11 positive than negative patients (p=0.04). Anti-cN1A autoantibodies were detected in 98/287 (34,1%) of IBM, 3/30 (10%) DM and 9/29 (31%) PM patients, p=0.03. Coexistence of anti NDUFA11 and anti-cN1A antibodies was observed in 3 IBM patients. Conclusion Our results reveal a new autoimmune target in the mitochondrial respiratory chain complex I that might be specifically associated with IBM. This is of particular interest as mitochondrial abnormalities are known histological findings in muscle biopsies of IBM patients. References [1]Galindo-Feria AS, Wang G, Lundberg IE. Autoantibodies: Pathogenic or epiphenomenon. Best Pract Res Clin Rheumatol. 2022;36(2):101767. [2]Herbert MK,et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016;75(4):696-701. NDUFA11 protein fragments (PrESTs) Legend Amino acid sequence and molecular weight of the protein fragments loaded on the western blot gel. NDUFA11, NADH dehydrogenase 1 α subcomplex 11; His6ABP, six histidine and albumin binding protein. Validation of bead array assay results with western blot Legend Western blot showing the reactivity of two IBM patients against the NDUFA11 protein fragments (PrEST1,2,3) expressed with a His6ABP tag. Patient#1 was reactive to PrEST1 and not to PrEST2 and 3 in the bead array assay while patient#2 did not display any reactivity. NDUFA11, NADH dehydrogenase 1 α subcomplex 11; His6ABP, six histidine and albumin binding protein. Disclosure of Interests Antonella Notarnicola: None declared, Cecilia Hellstrom: None declared, Begum Horuluoglu: None declared, Charlotta Preger: None declared, Francesco Bonomi: None declared, Boel De Paepe: None declared, Jan De Bleecker: None declared, Anneke J. van der Kooi: None declared, Marianne de Visser: None declared, Sabrina Sacconi: None declared, Pedro Machado: None declared, Umesh A. Badrising: None declared, Anke Rietveld: None declared, Ger Pruijn: None declared, Simon Rothwell: None declared, James B. Lilleker: None declared, Hector Chinoy: None declared, Olivier Benveniste: None declared, Elisabet Svenungsson: None declared, Helena Idborg: None declared, Per-Johan Jakobsson: None declared, Peter Nilsson: None declared, Ingrid E. Lundberg Shareholder of: stock shares in Roche and Novartis, Consultant of: Consulting fees from Corbus Pharmaceuticals, Inc and research grants from Astra Zeneca and has been serving on the advisory board for Astra Zeneca, Bristol Myers Squibb, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezaar, Orphazyme, Pfizer and Janssen.
- Open Access
- 6 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 207-208
POS0005 IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS, MUSCLE-RESTRICTED TCR CLONES SHARE STRUCTURAL FEATURES, WHILE THEIR EXPANSION CORRELATES WITH DISEASE ACTIVITY
Background T cells of different lineages including cytotoxic T cells have been implicated in the pathogenesis of idiopathic inflammatory myopathies [1]. However, the question of whether the T cell response in muscle is reflective of the peripheral blood response remains to be fully answered. Objectives To characterize the T cell receptor (TCRβ) repertoire in peripheral blood and muscle tissues of treatment naïve patients with newly diagnosed idiopathic inflammatory myopathies (IIMs). Methods High throughput RNA sequencing of the TCRβ chain was performed in peripheral blood and muscle tissue in twenty newly-diagnosed treatment-naïve IIM patients and healthy controls. Results thereof were correlated with markers of disease activity. Results Muscle tissue of IIM patients show more expansion of TCRβ clones and decreased diversity when compared to peripheral of IIM as well as healthy controls (both p=0.0001). Several expanded TCRβ clones in muscle tissue are tissue restricted and cannot be retrieved in peripheral blood. These clones have significantly longer CDR3 regions when compared to clones (also) found in circulation (p=0.0002), while their CDR3 region is more hydrophobic (pConclusion Network analysis of clones in muscle of IIM patients shows shared clusters of sequences across patients. Muscle-restricted TCRβ clones show specific structural features in their T cell receptor, and clonal TCR expansion in muscle tissue is associated with disease activity. These findings indicate that specific clonal T cell responses in muscle tissue act as key players in the pathogenesis of IIM. Reference [1]Mizuno, K., et al., Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome. Clin Exp Immunol, 2004. 137(1): p. 187-94 Acknowledgements: NIL. Disclosure of Interests None Declared.
- 6 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 207-208
Open AccessPOS0005 IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS, MUSCLE-RESTRICTED TCR CLONES SHARE STRUCTURAL FEATURES, WHILE THEIR EXPANSION CORRELATES WITH DISEASE ACTIVITY
Background T cells of different lineages including cytotoxic T cells have been implicated in the pathogenesis of idiopathic inflammatory myopathies [1]. However, the question of whether the T cell response in muscle is reflective of the peripheral blood response remains to be fully answered. Objectives To characterize the T cell receptor (TCRβ) repertoire in peripheral blood and muscle tissues of treatment naïve patients with newly diagnosed idiopathic inflammatory myopathies (IIMs). Methods High throughput RNA sequencing of the TCRβ chain was performed in peripheral blood and muscle tissue in twenty newly-diagnosed treatment-naïve IIM patients and healthy controls. Results thereof were correlated with markers of disease activity. Results Muscle tissue of IIM patients show more expansion of TCRβ clones and decreased diversity when compared to peripheral of IIM as well as healthy controls (both p=0.0001). Several expanded TCRβ clones in muscle tissue are tissue restricted and cannot be retrieved in peripheral blood. These clones have significantly longer CDR3 regions when compared to clones (also) found in circulation (p=0.0002), while their CDR3 region is more hydrophobic (pConclusion Network analysis of clones in muscle of IIM patients shows shared clusters of sequences across patients. Muscle-restricted TCRβ clones show specific structural features in their T cell receptor, and clonal TCR expansion in muscle tissue is associated with disease activity. These findings indicate that specific clonal T cell responses in muscle tissue act as key players in the pathogenesis of IIM. Reference [1]Mizuno, K., et al., Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome. Clin Exp Immunol, 2004. 137(1): p. 187-94 Acknowledgements: NIL. Disclosure of Interests None Declared.